Akari Therapeutics (AKTX) announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a Virtual Investor “What This Means” segment. As part of the segment, Mr. Gaslightwala discussed its novel spliceosome modulator payload, PH1, and the Company’s ongoing efforts to build on key data for its spliceosome modulator payload with further research ongoing on how the payload can also disrupt key drivers responsible for cancer cell growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
- Akari Therapeutics reiterates commitment to research on PH1
- Akari Therapeutics ‘just getting started,’ initiated with a Buy at Maxim
- Akari Therapeutics initiated with a Buy at Maxim
- Akari Therapeutics Shareholders Approve Key AGM Resolutions
- Akari Therapeutics releases ‘What This Means’ segment for investors